NPI 1740945351: Open Payments
NPI 1740945351. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$202 in 8 payments from 5 companies in 2025. Trend: 2023 $519 · 2024 $850 · 2025 $202
Food & beverage: $202
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 4 | $105 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $32 |
| Janssen Pharmaceuticals, Inc | 1 | $28 |
| ABBVIE INC. | 1 | $21 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
Products named: COBENFY, CAPLYTA, INVEGA SUSTENNA, VRAYLAR, UZEDY.
